Evommune’s Series C — Advancing New Therapies in Chronic Inflammatory DiseasesEvommune’s $115M Series COct 31Oct 31
Nomic Bio’s Series B — Making proteomics accessibleNomic’s $42M Oversubscribed Series B FinancingSep 17Sep 17
Radiant Biotherapeutics Series A — Bringing Multabodies to PatientsAnnouncement of Radiant’s $35M Series ASep 11Sep 11
Published inAmplitude VCA New Chapter in Precision Medicine: Announcing Amplitude’s Second FundCelebrating the closing of our second fundMay 28May 28
Published inAmplitude VCReverb Therapeutics — Redirecting endogenous cytokinesLaunching Reverb Therapeutics out of stealth mode to redirect endogenous cytokines using antibodiesNov 15, 2023Nov 15, 2023
Published inAmplitude VCTentarix — creating next-generation multi-functional biologicsAnnouncing our lead investment into a $35M Series B financing of antibody developer TentarixSep 6, 2023Sep 6, 2023
Published inAmplitude VCEvommune — bringing new immunology medicines to patientsAnnouncing $50M US Series B Round to advance several therapies to treat chronic immune diseasesApr 26, 2023Apr 26, 2023
Published inAmplitude VCRadiant BioTherapeutics — utilizing multabodies to transform antibody therapeuticsAnnouncing Radiant Biotherapeutics emerging out of stealth mode with $8M Seed Round and Two Pharma PartnershipsApr 25, 2023Apr 25, 2023
Published inAmplitude VCAbdera Therapeutics: utilizing radiopharmaceuticals to revolutionize cancer treatmentThe announcement of a $142M USD Series A + B FinancingApr 20, 2023Apr 20, 2023
Published inAmplitude VCDrugbank — scaling the world’s-leading online drug databaseClosing of a $9M oversubscribed seed round for DrugbankApr 11, 2022Apr 11, 2022
